Current Research Studies

BrainChild-03: Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for DIPG, DMG, or B7-H3-Positive Recurrent or Refractory Pediatric Central Nervous System Tumors

BrainChild-03

  • Condition(s): Recurrent and/or Refractory, Glioneuronal and Neuronal Tumors, Medulloblastoma, CNS Germ Cell Tumors, Low-Grade Glioma, Newly diagnosed, Choroid Plexus Tumors, Diffuse Midline Glioma (DMG), Ependymoma, Pilocytic Astrocytoma, Diffuse Intrinsic Pontine Glioma (DIPG), Brain Tumor, Atypical Teratoid/Rhabdoid Tumor, High-Grade Glioma, CNS Embryonal Tumors
  • Phase: I
  • Clinicaltrials.gov ID: NCT04185038

What is the goal of the study?

In this phase 1 clinical trial, Seattle Children's is testing CAR T-cell therapy in children and young adults with recurrent or refractory central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). Researchers are working to answer these questions: -Is this T-cell therapy safe to give to children and young adults with recurrent or refractory CNS tumors, including DIPG and DMG? -What is the best dose of this therapy?

Who can participate in the study?

This study might be a good fit for children and young adults who: - Are ages 1 to 26 years old - Have recurrent or refractory CNS tumors, including DIPG and DMG Researchers use many other factors to decide whether or not a patient can take part in a study (called includion or exclusion criteria). The study team at Seattle Children's can explain what these factors mean for you or your child.

Study Team: